Expression of SOX17: A Novel Marker in Ovarian Germ Cell Tumors
AM Leathersich, D Cao. Washington University School of Medicine, St. Louis, MO
Background: Ovarian germ cell tumors (GCT) are rare and range from benign to malignant lesions. A novel marker, SOX17, has recently been shown to distinguish seminoma from embryonal carcinoma in the testis. The goal of this study is to investigate the diagnostic utility of the transcription factor SOX17 in ovarian GCT's and non-GCT's.
Design: One hundred and three ovarian GCT's were retrieved including 27 dysgerminomas, 35 yolk sac tumors (YST), 5 Embryonal carcinomas (EC), 13 immature teratomas (IM), 8 mature teratomas (MT), 5 gonadoblastomas (GB), 6 combined carcinoid and teratoma, 1 carcinoid, and 2 struma ovarii. We also stained 72 primary non-GCT's of the ovary including 9 endometrioid carcinomas, 11 high grade serous carcinomas, 9 mucinous carcinomas, 1 transitional cell carcinoma (TCC), 13 clear cell carcinomas, 2 benign Brenner tumors, 2 neuroendocrine tumors, 7 juvenile granulosa cell tumors (GCT), 6 adult GCTs, 7 steroid cell tumors, 2 Sertoli-Leydig cell tumors, and 3 fibrothecomas. Unstained slides generated from 1 to 2 paraffin embedded tissue blocks per case were stained with SOX17 monoclonal antibody. Only nuclear staining was counted as positive. The percentage of tumor cells stained was scored semiquantitatively as 0 (no tumor cells staining), 1+(<30% cells), 2+(31-60% cells), 3+(61-90% cells), 4+(>90% cells).
Results: Twenty-five out of 26 (96%) dysgerminomas and 28 of 35 (80%) YST showed 3+ to 4+ (>60%) nuclear staining for SOX17. 100% of GB cases showed staining. IT was negative in 62% of cases. EC and MT were negative for SOX17.
|Carcinoid and Teratoma||7||0||0||0||0|